Abbott Laboratories
ABT
$132.59
$0.590.45%
NYSE
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 151.56% | 139.82% | 134.18% | 11.72% | 7.67% |
| Total Depreciation and Amortization | -3.26% | -2.25% | -0.77% | -0.40% | 0.59% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 42.27% | 43.76% | 50.00% | -6.74% | -7.39% |
| Change in Net Operating Assets | -440.68% | -251.35% | -272.40% | 60.70% | 5.38% |
| Cash from Operations | 14.39% | 25.30% | 17.86% | 33.27% | 6.01% |
| Capital Expenditure | -0.71% | -3.29% | -0.23% | -8.99% | -14.36% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | 41.18% | -- | -- | 100.00% | 93.83% |
| Divestitures | -100.00% | -97.50% | -97.50% | -97.50% | -97.50% |
| Other Investing Activities | -450.00% | -133.33% | -40.43% | -17.02% | 2.44% |
| Cash from Investing | -7.53% | 23.03% | 25.38% | 21.93% | 16.30% |
| Total Debt Issued | -97.94% | 873.91% | 869.57% | 2,118.18% | 575.00% |
| Total Debt Repaid | 38.76% | 35.35% | 69.58% | 27.98% | -8,196.88% |
| Issuance of Common Stock | 85.23% | 74.48% | 58.08% | 56.90% | 35.43% |
| Repurchase of Common Stock | -175.92% | -47.75% | -5.54% | 25.05% | 79.99% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -7.55% | -7.78% | -7.87% | -7.88% | -7.73% |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -3.62% | 8.37% | 23.79% | 13.87% | -11.58% |
| Foreign Exchange rate Adjustments | 152.83% | 46.27% | -317.39% | 300.00% | 17.19% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 95.75% | 108.62% | 124.11% | 129.43% | 23.05% |